Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 371

2.

Stroke prevention in atrial fibrillation: pooled analysis of SPORTIF III and V trials.

Albers GW; SPORTIF Investigators.

Am J Manag Care. 2004 Dec;10(14 Suppl):S462-9; discussion S469-73. Review.

3.

Antithrombotic therapy in atrial fibrillation: ximelagatran, an oral direct thrombin inhibitor.

Halperin JL.

Expert Rev Cardiovasc Ther. 2004 Mar;2(2):163-74. Review.

PMID:
15151465
4.
5.

Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation. Pooled analysis from the SPORTIF III and V studies.

Diener HC; Executive Steering Committee of the SPORTIFF III and V Investigators.

Cerebrovasc Dis. 2006;21(4):279-93. Epub 2006 Jan 5.

PMID:
16449807
6.

Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials.

Flaker GC, Gruber M, Connolly SJ, Goldman S, Chaparro S, Vahanian A, Halinen MO, Horrow J, Halperin JL; SPORTIF Investigators.

Am Heart J. 2006 Nov;152(5):967-73.

PMID:
17070169
7.

[Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?].

Selçuk H, Selçuk MT, Maden O.

Anadolu Kardiyol Derg. 2007 Mar;7(1):54-8. Review. Turkish.

9.

Effect of ximelagatran and warfarin on stroke subtypes in atrial fibrillation.

Teitelbaum JS, von Kummer R, Gjesdal K, Kristinsson A, Gahn G, Albers GW; SPORTIF Executive Steering Committee.

Can J Neurol Sci. 2008 May;35(2):160-5.

PMID:
18574928
10.

Preventing stroke in atrial fibrillation: the SPORTIF programme.

Lip GY.

Pathophysiol Haemost Thromb. 2005;34 Suppl 1:25-30. Review.

11.
12.

Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial.

Albers GW, Diener HC, Frison L, Grind M, Nevinson M, Partridge S, Halperin JL, Horrow J, Olsson SB, Petersen P, Vahanian A; SPORTIF Executive Steering Committee for the SPORTIF V Investigators.

JAMA. 2005 Feb 9;293(6):690-8.

PMID:
15701910
13.
14.

Prevention of stroke in patients with atrial fibrillation.

Olsson SB, Halperin JL.

Semin Vasc Med. 2005 Aug;5(3):285-92. Review.

PMID:
16123916
16.

Trials and tribulations of non-inferiority: the ximelagatran experience.

Kaul S, Diamond GA, Weintraub WS.

J Am Coll Cardiol. 2005 Dec 6;46(11):1986-95. Epub 2005 Nov 9.

17.

Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale.

Lopes RD, Alexander JH, Al-Khatib SM, Ansell J, Diaz R, Easton JD, Gersh BJ, Granger CB, Hanna M, Horowitz J, Hylek EM, McMurray JJ, Verheugt FW, Wallentin L; ARISTOTLE Investigators.

Am Heart J. 2010 Mar;159(3):331-9. doi: 10.1016/j.ahj.2009.07.035. Erratum in: Am Heart J. 2010 Jun;159(6):1162.

PMID:
20211292
18.
19.
20.

Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement.

Francis CW, Berkowitz SD, Comp PC, Lieberman JR, Ginsberg JS, Paiement G, Peters GR, Roth AW, McElhattan J, Colwell CW Jr; EXULT A Study Group.

N Engl J Med. 2003 Oct 30;349(18):1703-12.

Supplemental Content

Support Center